Membrane-type 1 matrix metalloproteinase expression is regulated by zonula occludens-1 in human breast cancer cells by Polette, M. et al.
Published in: Cancer Research (2005), vol. 65, iss. 17, pp. 7691-7698 
Status: Postprint (Author’s version) 
Membrane-Type 1 Matrix Metalloproteinase Expression Is Regulated by 
Zonula Occludens-1 in Human Breast Cancer Cells 
Myriam Polette,1 Christine Gilles,2 Béatrice Nawrocki-Raby,1 Jouko Lohi,3 Walter Hunziker,4 Jean-Michel 
Foidart,2 and Philippe Birembaut1*
 
1Institut National de la Sante et de la Recherche Medicale UMRS 514, Laboratory of Histology, IFR 53, CHU Maison Blanche, Reims, 
France; 
2Laboratory of Developmental and Tumor Biology, University of Liège, Liège, Belgium;  
3Department of Pathology, Haartman Institute, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; and  
4Institute of Molecular and Cell Biology, Epithelial Cell Biology Laboratory, Singapore, Singapore 
 
Abstract 
The acquisition of a migratory/invasive phenotype by tumor cells is characterized by the loss of cell-cell 
adhesion contacts and the expression of degradative properties. In this study, we examined the effect of the 
disorganization of occludin/zonula occludens (ZO)-1 tight junction (TJ) complexes on the expression of 
membrane-type 1 matrix metalloproteinase (MT1-MMP). We first compared the expression of MT1-MMP and 
the localization of occludin/ZO-1 complexes in breast tumor cell lines displaying various degrees of 
invasiveness. We showed that the expression of MT1-MMP in invasive breast tumor cell lines correlates with the 
absence of occludin and with a cytoplasmic localization of ZO-1. In contrast, noninvasive cell lines displayed a 
membrane staining for both ZO-1 and occludin and did not express MT1-MMP. In vivo, cytoplasmic ZO-1 and 
MT1-MMP could be detected in invasive tumor clusters of human breast carcinomas. We then used RNA 
interference strategy to inhibit ZO-1 expression in invasive BT549 cells and to evaluate the effect of ZO-1 down-
regulation on MT1-MMP expression. We observed that ZO-1 small interfering RNA transfection down-regulates 
MT1-MMP mRNAs and proteins and subsequently decreases the ability of tumor cells to invade a reconstituted 
basement membrane in a Boyden chamber assay. Inversely, transfection of expression vectors encoding wild-
type ZO-1 or the NH2-terminal fragment of ZO-1 comprising the PSD95/DLG/ZO-1 domains in BT549 activated 
a human MT1-MMP promoter luciferase reporter construct and increased cell invasiveness. Such transfections 
concomitantly activated the β-catenin/TCF/LEF pathway. Our results therefore show that ZO-1, besides its 
structural role in TJ assembly, can intervene in signaling events promoting tumor cell invasion.  
 
INTRODUCTION 
The acquisition of an invasive phenotype by epithelial tumor cells requires the disruption of intercellular 
adhesion. Although the reorganization of E-cadherin/β-catenin complexes of adherens junctions during tumor 
cell migration and invasion has been largely documented, little is known about the implication of tight junction 
(TJ) molecules  in  tumor progression  (1).  In normal epithelial cells, TJs are composed of transmembrane 
molecules (occludin, claudin, and junctional adhesion molecules) linked to the actin cytoskeleton through 
cytoplasmic submembranous components, including zonula occludens (ZO)-l, ZO-2, and ZO-3 (2, 3). ZO-1 (220 
kDa) interacts directly with the others TJ proteins through its different structural conserved domains, three 
PSD95/ DLG/ZO-1 (PDZ) domains, one Src homology 3 domain, and one guanylate kinase homologous (GK) 
domain. ZO-1 is thus able to bind occludin via the GK domain, some claudins via the first PDZ domain, ZO-2 or 
ZO-3 via the second PDZ domain, and actin via the COOH-terminal end (2). ZO-1 also binds other TJ proteins, 
such as AF-6 and cingulin (2). Because of its interactions with many TJ components, ZO-1 acts as a crucial 
central regulator of the structural organization of the TJs at the plasma membrane. In carcinomas, ZO-1 is 
generally considered a tumor suppressor (4). Indeed, several studies have reported that a reduction of ZO-1 
expression correlates with tumor dedifferentiation and progression in breast and colorectal carcinomas (5-7). It 
has also been shown that ZO-1 displayed a cytoplasmic distribution in breast carcinomas (7). In addition, ZO-1 
has been found overexpressed in primary and metastatic pancreatic cancers (8). Generating different ZO-1 
deletion constructs, it has been shown that a form of ZO-1, which lacks the GK domain and thus does not bind 
occludin and fails to be recruited to the plasma membrane, is able to confer tumorigenicity to transfected Madin-
Darby canine kidney I (MDCK I) cells injected into nude mice (9). In addition, migrating epithelial MDCK I 
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cells have been reported to display a ZO-1 nuclear localization (10). It has also been reported previously that 
ZO-1 contains several nuclear sorting signals, suggesting that ZO-1 shuttles between the plasma membrane and 
the nucleus (11). Based on these results, the concept has emerged that, in addition to its structural role in TJ 
organization, ZO-1, once delocalized from TJs, may be involved in signaling pathways favoring epithelial cell 
migration and invasion. 
Besides the loss of cell-cell contacts, tumor invasion is also characterized by the expression of degradative 
properties by tumor cells. Among the proteases implicated in this process, matrix metalloproteinases (MMP) 
occupy a central role. MMPs are a family of zinc endopeptidases comprising 25 members that degrade many 
extracellular matrix (ECM) components. Although the majority of MMPs are secreted as soluble enzymes, six 
membrane-bound MMPs have also been identified (12). Among the six membrane-type MMPs, membrane-type 
1 MMP (MT1-MMP), which possesses a transmembrane domain, has been particularly implicated in pericellular 
proteolysis associated with cell migration (13). In addition to the degradation of structural ECM components, 
such as fibronectin, vitronectin, laminin-1, laminin-5, fibrin, and collagen type I, II, and III, MT1-MMP can also 
degrade cell adhesion molecules, such as CD44 and αv, integrin, as well as some cytokines, including MCP-3, 
stromal cell-derived factor-1α, and pro-tumor necrosis factor-α (14). MT1-MMP is also known to be an activator 
of other MMPs, particularly of MMP-2. Owning these properties, MT1-MMP regulates various cell functions 
that contribute to enhanced metastatic abilities. MT1-MMP has indeed been shown to be associated with tumor 
progression, particularly in cell invasion, angiogenesis, and metastasis. Accordingly, several studies have 
described an over-expression of MT1-MMP in many types of human carcinomas (14). Moreover, numerous 
reports have indicated that MT1-MMP is produced by invasive tumor cells in vitro as well as in vivo (15). 
Interestingly, MT1-MMP expression in epithelial tumor cells has been shown to correlate with and be regulated 
by a reorganization of E-cadherin/β-catenin complexes (16, 17). These data emphasize a role of cell-cell contact 
molecules in the regulation of tumorpromoting genes, such as MMP. 
In the present study, we investigated the potential role of ZO-1 in the regulation of MT1-MMP in invasive tumor 
cells. We document an association between the reorganization of occludin/ZO-1 complexes and the expression 
of MT1-MMP in invasive breast tumor cell lines. We also report that ZO-1 small interfering RNA (siRNA) 
transfection in invasive cells decreases MT1-MMP expression and invasive properties. In addition, transfection 
of ZO-1 cDNA was found to concomitantly activate the MT1-MMP promoter and the β-catenin/TCF/LEF 
pathway. 
 
MATERIALS AND METHODS 
Cell culture 
All human mammary epithelial cells were obtained from the American Type Culture Collection (Rockville, 
MD). MCF-7, BT20, MDA-435, BT549, and Hs578T cells were cultured in DMEM containing 10% FCS. 
Transfection of small interfering RNA 
Three 19-nucleotide specific sequences were selected in the coding sequence of ZO-1 (Genbank accession no. 
L14837) to generate 21-nucleotide sense and 21-nucleotide antisense strands of the type (19N) TT (N, any 
nucleotide). The sense and antisense strands were then annealed to obtain duplexes with identical 3' overhangs. 
The sequences were submitted to a BLAST search against the human genome to ensure the specificity of the 
siRNA to the targeted sequence. Three corresponding scramble duplexes, which do not recognize any sequence 
in the human genome, were used as controls. The 19-nucleotide specific sequences for the three ZO-1 siRNAs 
are as follows: ZO-1 Sil, 5'-GUUAUACGAGCGAUCUCAU-3'; ZO-1 Si2, 5'-GGAGGAAACAG-
CUAUAUGG-3'; and ZO-1 Si3, 5'-GACGAGAUAAUCCUCAUUU-3'. For transfection of the siRNA duplexes, 
75,000 cells were plated in six-well plates in 2 mL/well of culture medium. Twenty-four hours after plating, the 
cells were transfected by phosphate calcium precipitation by adding in each well 200 µL of a mixture containing 
the siRNA duplexes (50, 20, or 2 nmol/L), 140 mmol/L NaCl, 0.75 mmol/L Na2HPO4, 6 mmol/L glucose, 5 
mmol/L KC1, 25 mmol/L HEPES, and 125 mmol/L CaCl2. Twenty-four hours after transfection, the cells were 
extensively washed with PBS and incubated for 48 hours in culture medium before they were harvested for 
reverse transcription-PCR (RT-PCR) analyses, Western blotting analyses, or Boyden chamber assays. 
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Transient transfections of zonula occludens-1 expression vectors and reporter assay 
 The expression vectors encoding wild-type ZO-1 (ZO-1-WT) or the NH2-terminal fragment of ZO-1 comprising 
the PDZ domains, ZO-1-PDZ (1-3), have been characterized previously (9). The MT1-MMP promoter luciferase 
reporter vector was constructed by subcloning a 1.2-kb fragment of the 5' promoter region of MT1-MMP (18) 
into the firefly luciferase reporter plasmid pGL-3 (Promega, Madison, WI). The TOP-FLASH and FOP-FLASH 
plasmids containing three wild-type (TOP-FLASH) or mutated (FOP-FLASH) copies of the β-catenin/TCF  
binding  sites upstream of a minimal herpesvirus thymidine kinase promoter driving the firefly luciferase 
expression were a kind gift from H.C. Clevers (University Hospital, Utrecht, The Netherlands; ref. 19). 
Transient transfections were done with Fugene transfection reagent (Roche, Indianapolis, IN). For 
immunofluorescence analyses, Boyden chamber assays, or preparation of cytosolic versus nuclear extracts, cells 
were plated in six-well plates or 10 cm Petri dishes 24 hours before the addition of the DNA/Fugene mixture. 
The cells were transfected according to the manufacturer's instructions with a mixture (100 µL for six-well plates 
and 400 µL for 10 cm Petri dish) containing 30 µL Fugene per 1 mL serum-free DMEM and 20 µg ZO-l-WT or 
ZO-l-PDZ expression vector (or the corresponding pLNCX empty vector). The cells were collected 24 or 48 
hours after transfection. For promoter luciferase assays, 50,000 cells were plated in 24-well plates 30 minutes 
before the addition of the DNA/Fugene mixture. Each well was incubated with a mixture containing 20 µL 
serum-free DMEM, 0.6 µL Fugene, 0.2 µg firefly promoter luciferase reporter plasmid (either the MT1-MMP 
promoter, the TOP-FLASH or the FOP-FLASH reporter construct), 0.2 µg ZO-l-WT or ZO-1-PDZ expression 
vector (or the corresponding pLNCX empty vector), and 0.8 ng Renilla luciferase expression vector phRG-TK 
(Promega). Twenty-four hours after transfection, the cells were lysed in 50 µL passive lysis buffer and the 
luciferase activity was determined with a luminometer using the Dual Luciferase Assay System (Promega) on 20 
µL lysate. For each experiment, the firefly luciferase activity was normalized to the activity of the Renilla 
luciferase used as internal control. The results were expressed as fold induction determined by normalizing each 
firefly luciferase value to the Renilla luciferase internal control value and by dividing these normalized values 
with the mean normalized value of the corresponding reporter construct transfected with the empty expression 
vectors. To assess the β-catenin/ TCF/LEF activities, the normalized values obtained with the FOP-FLASH 
reporter plasmid were subtracted from the normalized values obtained with the TOP-FLASH reporter plasmid. 
The resulting values were then divided with the mean normalized value of the condition transfected with the 
empty expression vector. Each experiment was done at least thrice in triplicate. Data are expressed as means ± 
SD. A nonparametric test (Mann-Whitney U test) was done and P < 0.05 was considered significant. 
Immunofluorescence 
Confluent monolayers of cells cultured on glass coverslips were fixed with methanol for 10 minutes at -20°C. 
For confocal microscopy analyses of ZO-1, cells were fixed in 2.5% paraformaldehyde in PBS for 30 minutes 
and then permeabilized with 0.2% Triton X-100 for 15 minutes at room temperature. The coverslips were then 
saturated for 10 minutes with 3% bovine serum albumin (BSA) in PBS. Monolayers were next (after 
intermediate washes in PBS) incubated for 1 hour with a monoclonal antibody to ZO-1 (Z01-1A12, Zymed 
Laboratories, San Francisco, CA) or occludin (OC-3F10, Zymed Laboratories) and then with a biotinylated anti-
mouse IgG (Amersham, Arlington Heights, IL) for 1 hour. Coverslips were exposed to Alexa Fluor 492-coupled 
streptavidin for 30 minutes (Molecular Probes, Eugene, OR). The coverslips were then mounted with 
Aquapolymount antifading solution (Agar, Essex, United Kingdom) onto glass slides and observed under a Zeiss 
fluorescence microscope or with a MRC-600 confocal laser scanning microscope (Bio-Rad, Richmond, CA). 
Western blotting analyses 
For ZO-1, occludin, and MT1-MMP detection, cells were rinsed twice in PBS and extracted in lysis buffer [50 
mmol/L Tris (pH 7.4), 150 mmol/L NaCl, 1% (v/v) Igepal, 1% (w/v) sodium deoxycholate, 5 mmol/L 
iodoacetamide, 0.1% (w/v) SDS] containing Complete protease inhibitor cocktail (Roche). To examine the 
subcellular distribution of β-catenin, cytosolic and nuclear extracts of BT549 cells transfected with the ZO-1-WT 
or ZO-l-PDZ expression vectors (or the corresponding pLNCX empty vector) were done using the ProteoExtract 
Subcellular Proteome Extraction kit (Calbiochem, La Jolla, CA). Protein concentration was determined with the 
detergent-compatible protein assay (Bio-Rad). Total protein (10 µg) was separated on 7.5% and 12% SDS-
PAGE gels for ZO-1 and for occludin and MT1-MMP analyses, respectively. Cytosolic extracts (4 µg) or 
nuclear extracts (2 µg) were separated on 10% SDS-PAGE to analyze the expression of β-catenin. The proteins 
were transferred to polyvinylidene difluoride membranes (NEN, Boston, MA), which were then blocked with 
5% milk (w/v), 0.1% Tween 20 (w/v) in PBS for 2 hours before exposure to the primary antibody overnight at 
4°C: a monoclonal antibody to ZO-1 (ZO1-1A12), a monoclonal antibody to occludin (OC-3F10), a monoclonal 
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antibody directed against the hemopexin-like domain of MT1-MMP (clone 2D7, kindly provided by Dr. Rio, 
Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch, France), and a monoclonal antibody 
directed against the unphosphorylated form of β-catenin (clone 8E4, A.G. Scientific, San Diego, CA). The filters 
were then incubated with either a horseradish peroxidase-conjugated goat anti-rabbit or swine anti-mouse 
antibody (DAKO, Glostrup, Denmark). Signals were detected with an Enhanced Chemiluminescence Plus kit 
(Amersham Pharmacia Biotech, Buckinghamshire, United Kingdom). Subsequent detection of actin (using a 
rabbit antibody to actin, clone A2066, Sigma-Aldrich, St. Louis, MO) or c-myc (using a monoclonal antibody to 
c-myc, clone 9E10, Sigma-Aldrich) was done on the same filters as a control. The values obtained for MT1-
MMP were normalized to values obtained for actin in three independent transfection experiments. Results were 
expressed as fold induction determined by dividing the normalized value with the normalized value of the 
corresponding scrambled siRNA control. Data are expressed as means ± SD. A nonparametric test (Mann-
Whitney U test) was done and P < 0.05 was considered significant. 
Reverse transcription-PCR analyses 
Total RNA extraction was done with the RNA isolation kit (Roche). RT-PCR was done using 10 ng total RNA 
the GeneAmp Thermostable RNA PCR kit (Perkin-Elmer, Foster City, CA), and pairs of primers for human 
MT1-MMP and for 28S rRNA (Eurogentec, Seraing, Belgium). Forward and reverse primers for human MT1-
MMP and 28S were designed as follows: MT1-MMP primers (forward 5'-
GGATACCCAATGCCCATTGGCCA-3' and reverse 5'-CCATTGGGCATCCAGAAGAGAGC-3') and 28S 
primers (forward 5'-GTTCACCCACTAATAGGGAACGTGA-3' and reverse                                                             
5'-GGATTCTGACTTAGAGGCGTTCAGT-3'). Reverse transcription was done at 70°C for 15 minutes. 
Amplification cycles were as follows: 15 seconds at 94°C, 20 seconds at 68°C, and 10 seconds at 72°C. Twenty 
cycles were allowed for MT1-MMP amplification and 15 cycles for 28S amplification. Products were separated 
on acrylamide gels, stained with SYBR Gold (Molecular Probes), and quantified by fluorimetric scanning (LAS-
1000, Fuji, Stamford, CT). The values obtained for MT1-MMP amplification were normalized to the values 
obtained for 28S amplification in three independent transfection experiments. Results were expressed as fold 
induction determined by dividing the normalized value of a given siRNA with the normalized value of the 
corresponding scrambled siRNA control. Data are expressed as means ± SD. A nonparametric test (Mann-
Whitney U test) was done and P < 0.05 was considered significant. 
Modified Boyden chamber invasion assay 
The in vitro invasive properties of transfected cells were assessed using a modified Boyden chamber assay. Cells 
(104) were suspended in 30 µL serum-free medium supplemented with 0.1% BSA and placed in the upper 
compartment of a 48-well invasion chamber (Neuroprobe, Pleasanton, CA). The lower compartment of the 
chamber was filled with 30 µL medium containing 10% FCS and 1% BSA The two compartments were 
separated by a porous filter (8 µm pore, Nucleopore, Pleasanton, CA) coated with Matrigel (1 mg/10 mL used to 
coat the filter). After 24 hours of incubation at 37°C, the filters were fixed in methanol for 10 minutes and 
stained with hematoxylin for 5 minutes. The cells at the upper surface of the filters were wiped away with a 
cotton swab. Quantification of the invasion assay was done by counting the number of cells at the lower surface 
of the filters (10 fields at 400-fold magnification). Experiments were done at least thrice in triplicate. Data are 
expressed as means ± SD. A nonparametric test (Mann-Whitney U test) was done and P < 0.05 was considered 
significant. 
Immunohistochemistry on breast tissues 
Human tissues were obtained from biopsies of 15 invasive breast ductal carcinomas. The samples were fixed in 
formalin and embedded in paraffin. Immunohistochemistry for ZO-1 and MT1-MMP was done on 5 µm serial 
sections. The sections were deparaffinized, rehydrated, and treated with 0.3% H2O2 for 5 minutes to quench 
endogenous peroxidase activity. Slides were then incubated for 30 minutes with a monoclonal antibody to either 
ZO-1 (ZO1-1A12) or MT1-MMP (clone 113-B7, Oncogene Science, Cambridge, MA). After several washes, the 
slides were successively incubated with biotin-coupled anti-mouse antibody (DAKO) and then with a 
horseradish peroxidase-conjugated streptavidin (DAKO). The peroxidase activity was revealed using the LSAB 
kit (DAKO). The slides were briefly counterstained with Mayer's hematoxylin, mounted, and observed under a 
Zeiss Axiophot microscope. 
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RESULTS 
Membrane-type 1 matrix metalloproteinase is expressed by invasive, occludin-negative breast tumor cell 
lines 
To examine the relationship between the presence or localization of occludin/ ZO-1 complexes and MT1-MMP 
expression, we first examined the expression of these three molecules in two noninvasive (MCF-7 and BT20) 
and three invasive (MDA-435, BT549, and Hs578T) epithelial breast cancer cell lines. The invasive phenotype 
of these breast cancer cells, assessed by a modified Boyden chamber assay, has been characterized in previous 
studies and was confirmed in our present study (data not shown; refs. 20-22). By Western blotting, we observed 
an inverse correlation between occludin and MT1-MMP expression. Occludin was only detected in noninvasive 
cell lines, whereas MT1-MMP was only found in invasive cell lines. In contrast, ZO-1 was expressed in all the 
cell lines analyzed regardless of their invasive properties (Fig. 1). 
The cytoplasmic localization of zonula occludens-1 correlates with invasiveness of tumor cells 
We then examined more closely the subcellular localization of occludin and ZO-1 in the different tumor cell 
lines. By immunofluorescence microscopy, we found that occludin was present at the cell membrane of 
noninvasive tumor cells (as illustrated in MCF-7 in Fig. 2A) and was absent in invasive tumor cells (as illustrated 
in BT549 in Fig. 2A ). Regarding ZO-1, we observed that ZO-1 was mainly localized at the membrane of 
noninvasive cells, whereas it showed a predominantly diffuse cytoplasmic staining in invasive tumor cells (Fig. 
2A and B). 
ZO-1 and MT1-MMP expression was also observed in several cases of human ductal breast carcinomas. Staining 
of serial sections of breast carcinomas with ZO-1 and MT1-MMP antibodies revealed the concomitant 
expression of MT1-MMP and ZO-1 in invasive tumor clusters, where ZO-1 showed a heterogenous cytoplasmic 
localization (Fig. 3). Although in all cases ZO-1 was expressed in tumor cells staining for MT1-MMP, not all 
MT1-MMP-positive cells showed ZO-1 labeling. 
 
Figure 1. Expression of occludin, ZO-1, and MT1-MMP in human breast cancer cell lines. Western blot 
analyses of ZO-1, occludin, and MT1-MMP were done on five human tumor cell lines (MCF-7, BT20, MDA-435, 
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Figure 2. Localization of occludin/ZO-1 in human tumor cell lines. A, ZO-1 and occludin immunolabeling in 
MCF-7 and BT549 monolayers. Bar, 50 µm. B, confocal microscopy analyses of ZO-1 localization in MCF-7 




Regulation of membrane-type 1 matrix metalloproteinase expression by zonula occludens-1 
To evaluate the potential implication of ZO-1 in the regulation of MT1-MMP expression, we used a RNA 
silencing strategy to down-regulate the endogenous ZO-1 levels in three invasive tumor cell lines. Transfection 
of a siRNA against ZO-1 down-regulated ZO-1 expression in the three cell lines at the protein level (Fig. 4). We 
concomitantly observed a clear diminution of MT1-MMP protein in tumor cells treated with the ZO-1 siRNA 
compared with cells treated with scrambled control siRNA (Fig. 4). Because the siRNA-mediated down-
regulation of ZO-1 worked best in BT549 cells, we used this cell line to further investigate the regulation of 
MT1-MMP expression by ZO-1. To exclude a potential nonspecific effect of the ZO-1 siRNA used above, we 
first confirmed our results using two different siRNAs against ZO-1. As revealed by RT-PCR analyses, all three 
ZO-1 siRNAs significantly reduced MT1-MMP mRNA expression in BT549 tumor cells compared with 
scrambled control siRNAs (0.46 ± 0.06, 0.52 ± 0.05, and 0.71 ± 0.04 for Si-1, Si-2, and Si-3, respectively; P < 
0.05; Fig. 5B and C). Accordingly, Western blotting also revealed a significant decrease of the 60-kDa active 
form of MT1-MMP (0.5 ± 0.05, 0.28 ± 0.05, and 0.22 ± 0.05 for Sil, Si-2, and Si-3, respectively; P < 0.001; Fig. 
5D and E). Concomitantly, we also observed a down-regulation of the 45-kDa form of MT1-MMP (Fig. 5E). As 
shown in Fig. 6, the inhibiting effect of ZO-1 Si3 siRNA on MT1-MMP expression is observed at various 
concentrations of siRNA. We also tested the effect of ZO-1 silencing on cell invasion in the Boyden chamber 
assay and observed that ZO-1 Si3 siRNA at 2, 20, and 50 nmol/L significantly reduced the invasive properties of 
the BT549 cells (435 ± 40 versus 150 ± 15, 468 ± 69 versus 70 ± 9, and 453 ± 43 versus 55 ± 2.9 cells per 10 
fields for 2, 20, and 50 nmol/L concentrations of scrambled Si3 siRNA versus ZO-1 Si3 siRNA, respectively; P 
< 0.001; Fig. 6B). 
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Figure 3. Cytoplasmic ZO-1  and MT1-MMP expression in ductal breast carcinomas. ZO-1 (A) and MT1-MMP 
(B) immunolabelings are detected on invasive tumor cells (T) in ductal breast carcinomas. 
 
 
Figure 4. Down-regulation of MT1-MMP expression in invasive tumor cell lines by ZO-1 siRNA. Western blot 
analyses of ZO-1, MT1-MMP, and actin expression were done on total extracts of MDA-435, BT549, and Hs578T transfected with the ZO-1 
Si3 siRNA or its corresponding scrambled control siRNA at a 50 nmol/L concentration. HT1080 cells treated with concavalin A (HT1080+) 
were used as a control to reveal the two forms of MT1-MMP at 60 and 45 kDa. 
 
Zonula occludens-1 regulates the membrane-type 1 matrix metalloproteinase promoter and activates the 
β-catenin/TCF/ LEF transcriptional activity 
It has been shown previously that the NH2-terminal part of ZO-1 encompassing the three PDZ domains is able to 
activate the β-catenin/TCF pathway in MDCK I cells (9).  β-catenin, once delocalized from the adherens 
junction, can indeed accumulate in the cytoplasm, translocate to the nucleus, and, through binding to TCF/LEF 
transcription factors, directly regulate the transcription of genes implicated in tumor invasion (1). We thus 
examined the possibility that the regulation of MT1-MMP by ZO-1 could be associated with the activation of 
this pathway. For this purpose, BT549 tumor cells were transiently cotransfected with expression vectors 
encoding the NH2-terminal portion of ZO-1, including the three PDZ domains (ZO-1-PDZ) or ZO-l-WT and a 
MT1-MMP promoter reporter plasmid or the TOP-FLASH/FOP-FLASH reporters. First, we observed that 
transient transfection of ZO-1-WT and ZO-1-PDZ expression vectors increased the cytoplasmic labeling of ZO-1 
in BT549 cells and their invasiveness in Boyden chamber assays (1.97 + 0.25- and 1.89 + 0.16-fold induction for 
ZO-l-WT and ZO-1-PDZ transfection, respectively; Fig. 1A and B). We also found that both ZO-1-WT and ZO-
1-PDZ expression vectors significantly increased the activity of the MT1-MMP promoter in BT549 tumor cells 
(3.11 + 0.3- and 2.48 + 0.3-fold induction for ZO-l-WT and ZO-l-PDZ transfection, respectively; P < 0.001; Fig. 
7C). This was accompanied by an increased activity of the TOP-FLASH reporter system (9.12 + 3.6- and 5.85 + 
1.96-fold induction for ZO-l-WT and ZO-l-PDZ transfection, respectively), attesting of the activation of the β-
catenin/TCF/LEF pathway following ZO-l-WT and ZO-l-PDZ transfection (P < 0.001; Fig. 7D). It has been 
shown that the NH2-terminal unphosphorylated form of β-catenin is involved in the transcriptional activity of β-
catenin (23). Using an antibody specific for the unphosphorylated form of β-catenin, we therefore examined by 
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Western blotting the presence  of this particular form  of β-catenin in cytosolic or nuclear extracts of cells 
transfected with ZO-1-WT and ZO-1-PDZ expression vectors. Consistent with the results obtained with the 
TOP-FLASH reporter assays, we found an accumulation of the unphosphorylated form of β-catenin in the 
nucleus of ZO-1-WT or ZO-1-PDZ-transfected cells compared with control vector transfected cells (Fig. 7E). 
 
Figure 5. Down-regulation of MT1-MMP expression by ZO-1 siRNAs. BT549 tumor cells were transfected with three 
different ZO-1 siRNAs (Si1-Si3) or their corresponding scrambled control siRNAs (ScrSi1-ScrSi3) at 50 nmol/L. A, Western blot analyses 
of ZO-1 expression in BT549 cells transfected with the siRNAs. B, RT-PCR analyses of MT1-MMP and 28S expression in BT549 cells 
transfected with the siRNAs. C, quantification of RT-PCR analyses of MT1-MMP mRNA normalized with 28S values. Data are fold 
induction relative to the scrambled siRNA controls (P < 0.05). D, Western blot analyses of MT1-MMP and actin expression in BT549 cells 
transfected with the ZO-1 siRNAs. HT1080 cells treated with concavalin A (HT1080+) were used as a control to reveal the two forms of 
MT1-MMP at 60 and 45 kDa. E, quantification of the level of the 60 kDa activated MT1-MMP protein normalized to actin levels. Data are 
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Figure 6.  Effect of ZO-1 siRNAs on in vitro cell invasion. BT549 tumor cells were transfected with either ZO-1 
Si3 siRNA or the scrambled Si3 control siRNA at 2, 20, or 50 nmol/L. A, Western blot analyses of MT1-MMP expression in 
the transfected cells. Actin was used as a loading control. B, analysis of the invasive capacity of ZO-1 siRNA-transfected BT549 cells 




In the present study, we have shown that (a) the lack of occludin expression and the cytoplasmic localization of 
ZO-1 correlates with the invasive phenotype of tumor cells, (b) MT1-MMP is expressed only in the occludin-
negative invasive tumor cell lines, (c) ZO-1 and MT1-MMP can be detected in invasive tumor clusters in breast 
carcinomas, (d) the reduction of ZO-1 in invasive tumor cells decreases the expression of MT1-MMP and their 
invasive properties, and (e) the activation of the MT1-MMP promoter by ZO-1 is associated with the activation 
of the β-catenin/TCF/LEF signaling pathway. 
We first showed that occludin was detected only in noninvasive tumor cells as a membrane staining. This agrees 
with several reports showing that the loss of occludin expression correlates with tumor progression in human 
endometrial and prostate carcinomas (24, 25). Similarly, in vitro, occludin was also observed in well-
differentiated epithelial cell lines but not detected in invasive tumor cells and in dedifferentiated epithelial cell 
lines (9, 26, 27). These findings strengthened the hypothesis that occludin expression could be a hallmark of a 
noninvasive status. Interestingly, we also found that, although ZO-1 was present in all cell lines, it was present in 
the cytoplasm of invasive tumor cells, whereas in noninvasive cells it localized to the plasma membrane. 
Accordingly, Gottardi et al. have described that ZO-1 delocalizes from the plasma membrane in migrating 
epithelial cells at the edge of wounded monolayers, correlating with dedifferentiation of these cells and 
suggesting that ZO-1 may have a role in signaling events (10). In vivo, we found a diffuse cytoplasmic 
distribution of ZO-1 in breast tumors as also reported by Martin et al. (7). Taken together, these data show that a 
reorganization of membrane-associated occludin/ZO-1 complexes is associated with enhanced migratory and 
invasive properties of epithelial tumor cells and agree with the general concept describing that the acquisition of 
an effective invasive phenotype is related to a dedifferentiation of the epithelial tumor cells. 
The redistribution of ZO-1 in invasive tumor cells suggests that, besides its role in cell-cell adhesion, ZO-1 is 
implicated in the regulation of invasive genes. Accordingly, we show that the accumulation of ZO-1 in the 
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cytoplasm is associated with the expression of MT1-MMP in invasive tumor cell lines, a correlation that can also 
be observed in invasive tumor clusters of breast carcinomas. In the literature, it has been repeatedly reported that 
MT1-MMP is associated with the migratory and invasive phenotype of tumor cells; in particular, MT1-MMP has 
been directly implicated in the migration/invasion of several dedifferentiated cell lines (15, 28-31). More than a 
correlation, we now show that ZO-1 can modulate MT1-MMP levels. Indeed, the down-regulation of ZO-1 
levels by siRNAs clearly decreased MT1-MMP expression in invasive tumor cells as well as their in vitro 
invasive capacity. Inversely, the transfection of ZO-1 into BT549 cells increased the MT1-MMP promoter 
activity and their invasive properties. Only a few studies have implicated ZO-1 in the regulation of gene 
expression. The Drosophilia orthologue of ZO-1, tamou, has been linked to the regulation of the 
extramacrochaetae gene that participates in neural development (32). Balda and Matter have shown that ZO-1 
via its interaction with a Y-box transcription factor, ZO-1-associated nucleic acid-binding protein, regulates 
ErbB-2 expression, thereby modulating epithelial cell differentiation and morphogenesis (33). In addition, the 
NH2-terminal three PDZ domains of ZO-1, which by themselves are unable to localize to the plasma membrane 
and accumulate in the cytoplasm, promote a phenotypic conversion characterized by the repression of epithelial 
markers and the induction of mesenchymal features in transfected MDCK I and corneal epithelial cells (9, 34). In 
these studies, transfection of full-length ZO-1 led to its recruitment to the plasma membrane in MDCK I cells 
and did not induce any phenotypic conversion. This emphasized that ZO-1, once delocalized from the cell 
membrane, could play a role in the regulation of genes controlling cell differentiation (9, 34). Interestingly, in 
our experiments, transient transfection of either the PDZ domains or the full-length ZO-1 construct activated the 
human MT1-MMP promoter in invasive BT549 tumor cells. Our cells do not express occludin, which is required 
to maintain ZO-1 to the TJ plasma membrane, likely explaining why, in contrast to MDCK I cells, full-length 
ZO-1 also mediates an effect. Taken together, our results provide evidence that ZO-1 can regulate MT1-MMP 
expression and could thereby modulate the invasive properties of epithelial tumor cells. 
The mechanisms by which ZO-1 affects the expression of tumor-promoting genes, such as MT1-MMP, remain 
unclear. Because of its delocalization in dedifferentiated epithelial cells, it would be pertinent to believe that ZO-
1, once delocalized from the cell membrane, could modulate specific transcriptional pathways that control the 
expression of invasion-associated genes. 
An interaction between ZO-1 and the β-catenin/TCF/LEF pathway has accordingly been documented. Reichert 
et al. have indeed reported the activation of the β-catenin/TCF/LEF transcription pathway following the 
transfection of MDCK I cells with the ZO-1-PDZ construct (9). In agreement with the results in MDCK I cells, 
transfection of BT549 cells with the Z0-1-PDZ and the Z0-1-WT construct activated the β-catenin/TCF/LEF 
pathway concomitantly with the MT1-MMP promoter. Consistent with the activation of β-catenin/TCF/LEF 
transcriptional activity, the unphosphorylated form of β-catenin accumulated in the nucleus of BT549 cells 
transfected with Z0-1-WT and ZO-l-PDZ compared with vector transfected cells. This agrees with the literature 
data showing that the unphosphorylated form of β-catenin is implicated in the transcriptional activity of                   
β-catenin in the nucleus (23), although the selective binding of β-catenin to E-cadherin or TCF/LEF factors does 
only rely on the NH2-terminal unphosphorylated status of β-catenin (35). Thus, although the implication of                 
β-catenin-independent regulatory mechanisms cannot be excluded, our data suggest that the delocalization of 
ZO-1 could activate the β-catenin/TCF/LEF pathway, which could in turn induce MT1-MMP expression. 
Indeed, MT1-MMP has recently been reported to be a target gene of the β-catenin/TCF/ LEF pathway and                
β-catenin was shown to activate MT1-MMP transcription via its interaction with a TCF-binding element present 
in the MT1-MMP promoter (16, 17). The mechanism by which ZO-1 affects the β-catenin pathway is still 
unknown and a direct link between ZO-1 and β-catenin has not been established. Nevertheless, ZO-1 could 
interact with other molecules of the Wnt signaling pathway or of adherens junctions, thereby modulating the β-
catenin signaling functions. For instance, in cells lacking TJs or in early stages of cell-cell adhesion of epithelial 
cells, ZO-1 has been reported to directly bind to α-catenin, a molecule that links the actin cytoskeleton to the                     
E-cadherin/β-catenin complex, suggesting, that under certain conditions, α-catenin acts as a linker between ZO-1 
and β-catenin (36, 37). More recently, ZO-1 and ZO-2 have been implicated in localizing ARVCF, which, like β-
catenin, is an armadillo repeat protein and also binds to E-cadherin,   to   the   plasma   membrane   or   the   
nucleus (38). 
Irrespective of the precise mechanism involved, our data are consistent with a scenario where ZO-1, if 
delocalized from TJ, can activate the β-catenin/TCF/LEF pathway, which in turn could regulate the expression of 
MT1-MMP. 
In conclusion, our data establish a correlation between MT1-MMP expression and a cytoplasmic deloalization of 
ZO-1 in invasive occludin-negative tumor cells. Furthermore, we show that ZO-1 contributes to tumor cell 
invasion by modulating MT1-MMP expression likely via activation of β-catenin/TCF/LEF transcriptional 
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activity. These findings emphasize the dual role of adhesion molecules, such as ZO-1, as structural components 
of cell-cell junctions in noninvasive epithelial cells and as contributing factors to tumor progression through their 
ability to induce the expression of tumor-promoting genes in invasive cells. 
 
Figure 7. Activation of β-catenin/TCF/LEF pathway and MT1-MMP promoter by ZO-1. A, immunofluorescence 
analyses of the localization of ZO-1 in BT549 tumor cells transfected with the empty expression vector (pLNCX), the ZO-1-WT expression 
vector (ZO-1), or the NH2-terminal ZO-1-PDZ expression vector (PDZ). B, Boyden chamber analyses of the invasive capacity of BT549 
cells transfected with ZO-1 -WT (ZO-1 ) or ZO-1 -PDZ (PDZ) or the control vector (pLNCX). Data are fold induction relative to the 
transfection of the empty expression vector (P < 0.001). C, MT1-MMP promoter reporter assay. BT549 tumor cells were cotransfected with a 
human MT1-MMP promoter luciferase reporter plasmid and either the empty expression vector (pLNCX), the ZO-1-WT expression vector 
(ZO-1), or the NH2-terminal ZO-1-PDZ expression vector (PDZ). Data are fold induction relative to the cotransfection of the MT1-MMP 
reporter plasmid with the empty expression vector (P < 0.001). D, TOP-FLASH/FOP-FLASH reporter assay. The TOP-FLASH or FOP-
FLASH reporter plasmids were cotransfected with the empty expression vector (pLNCX), the ZO-1 -WT expression vector (ZO-1 ), or the 
ZO-1 -PDZ expression vector (PDZ) in BT549 tumor cells. The normalized FOP values were subtracted from the normalized TOP values. 
Data are fold induction relative to the values obtained in the controls transfected with the empty expression vector (P < 0.001). E, Western 
blot analyses of the unphosphorylated form of β-catenin in cytosolic and nuclear fractions of BT549 cells transfected with either the empty 
expression vector (pLNCX), the ZO-1-WT expression vector (ZO-1), or the NH2-terminal ZO-1-PDZ expression vector (PDZ). Actin and c-
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